Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (15841)	2/22/2005 4:00:31 PM
From: Extra Pale	Read Replies (2) \| Respond to of 52153

LGND: Listened to some of the Roth capital webcast today. Believe the ceo projected revenues of $400+m in 2006. Seems that even if Targretin in NSLC is not a homerun there are plenty of other interesting compounds in the pipeline. So once again I'm back in -- "so much potential they can't possible screw it all up"

To: Biomaven who wrote (15841)	3/6/2005 1:10:39 PM
From: CapitalistHogg™	Read Replies (3) \| Respond to of 52153

I really don't know if there's any good way to handicap this Targretin trial. It would take me many years (if ever?) to become as proficient as you at analyzing the science of biotech. That being said I do know a thing or two about options and binary events. LGND is definitely showing up as a binary event and most likely involves the phase III approval of Targretin. Take a look at the option volume last Friday. Almost 40 thousand contracts were traded primarily on the May 12.50 and May 17.5 calls. To me this indicates a bull call spread and shows heavy optimism for approval by somebody big. And while their are no "bargains to be had" I think that an unhedged wager on the stock would definitely have a good Risk/Reward profile. I would appreciate any thoughts you had on this Peter. TIA Bighogg